CHICAGO, US, July 9 (UrduPoint / Pakistan Point News – July 9, 2021) -: Drugmaker Pfizer-BioNTech on Friday announced it is asking the United States Food and Drug Administration to approve their new recall of COVID, which they say would increase protection against the virus.
Companies began researching the effectiveness of a third recall in February, as a way to protect against possible variants of COVID-19.
The new booster they’ve developed does not specifically target any variant of COVID, and U.S. health officials have previously said that current vaccines on the market protect against the burgeoning Delta variant.
But Pfizer-BioNTech says it has seen “encouraging data” that their booster injection, in general, provides more effective COVID protection when given within six months of the second dose.
Separately, Pfizer said it was working on a vaccine only to target the Delta variant, in case it was needed, and will begin clinical trials in August.
Some industry experts have warned that profit could be a bigger motivator for drug companies looking to get new vaccines approved by the FDA.
But Pfizer highlighted the situation in Israel: The nation has seen an earlier and more effective vaccine rollout than in many other countries. Seven months later, however, the vaccine’s efficacy appears to be waning as the Delta variant spreads and the Israeli government reinstated an indoor mask mandate.
In the United States, the problem remains vaccine reluctance colliding with the Delta variant, which may be more transmissible and more dangerous. Virtually all of the COVID deaths recorded in the United States are now from people who have not received any vaccines, and the Delta variant has become the dominant strain of COVID in the country.